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Abstract
Background: Gene targeting in vivo provides a potentially powerful method for gene analysis and
gene therapy. In order to sensitively detect and accurately measure designed sequence changes, we
have used a transgenic mouse system, MutaMouse, which has been developed for detection of
mutation in vivo. It carries bacteriophage lambda genome with lacZ+ gene, whose change to lacZ-
negative allele is detected after in vitro packaging into bacteriophage particles. We have also
demonstrated that gene transfer with a replication-defective adenovirus vector can achieve efficient
and accurate gene targeting in vitro.
Methods: An 8 kb long DNA corresponding to the bacteriophage lambda transgene with one of
two  lacZ-negative single-base-pair-substitution mutant allele was inserted into a replication-
defective adenovirus vector. This recombinant adenovirus was injected to the transgenic mice via
tail-vein. Twenty-four hours later, genomic DNA was extracted from the liver tissue and the
lambda::lacZ were recovered by in vitro packaging. The lacZ-negative phage was detected as a plaque
former on agar with phenyl-beta-D-galactoside.
Results: The mutant frequency of the lacZ-negative recombinant adenovirus injected mice was at
the same level with the control mouse (~1/10000). Our further restriction analysis did not detect
any designed recombinant.
Conclusion:  The frequency of gene targeting in the mouse liver by these recombinant
adenoviruses was shown to be less than 1/20000 in our assay. However, these results will aid the
development of a sensitive, reliable and PCR-independent assay for gene targeting in vivo mediated
by virus vectors and other means.
Background
Gene targeting, which is the precise alteration of genomic
information by homologous recombination, has pro-
vided a powerful means of genetic analysis in
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microorganisms and mammalian systems [1]. In mouse
systems, embryonic stem-cell lines modified in vitro can
be used to generate mice that are altered at the germ-line
level. If the gene targeting of somatic cells is made possi-
ble by gene transfer in vivo, it will facilitate the analysis of
gene function, and provide a means of gene therapy for
genetic and other diseases [2].
There are two major inherent problems with the use of
gene targeting in vivo. First, its low efficiency makes it dif-
ficult to detect and analyze. A sensitive and accurate meas-
urement system is therefore needed to detect such low-
frequency events. Although there have been several
reports of gene targeting in the rat liver with specifically
designed oligonucleotides [3,4], their reproducibility
remains controversial [5]. PCR-based detection methods
might thus be inaccurate and prone to various artifacts. In
order to detect and measure gene targeting in mice with
sufficient sensitivity, we used a bacteriophage transgenic-
mouse system, MutaMouse, which has been developed for
the detection of mutagenesis in vivo (Figure 1) [6]. The
MutaMouse carries tandem repeats of the bacteriophage
lambda genome with the lacZ+ gene, in which the change
to a lacZ-negative allele is detected after its in vitro packag-
ing into viable bacteriophage particles.
The second major problem with gene targeting in vivo is
that non-homologous recombination is much more fre-
quent than homologous recombination in mammalian
cells. Rare accurately modified cells are selected and puri-
fied in the case of embryonic stem cells that are treated in
vitro. For gene targeting in vivo, imprecise modification
would be detrimental for analytical uses and therapeutic
purposes. Accurate gene modification has been achieved
efficiently using replication-defective adenovirus vectors
for gene delivery in vitro [7,8]. Fujita and colleagues used
a mammalian plasmid as a model target [7]. The gene tar-
geting was frequent (~10-4 per cell) and analysis of the
products revealed that homologous recombination was
more frequent than non-homologous recombination.
One possible reason for this high accuracy was protection
of the viral DNA by the terminal protein, which is cova-
lently attached to the ends of the viral DNA and to other
viral proteins during its transfer to the nucleus and target
DNA. Breaks in unprotected DNA would lead to non-
homologous recombination.
The adenovirus is useful for gene delivery in vivo because
it has a broad host-range, is easy to prepare to a high titer
and only rarely integrates into the host genome by non-
homologous recombination [9,10]. To date, more than
170 clinical studies have used recombinant adenovirus
vectors to express cDNA in humans [11]. Numerous ade-
novirus-infection experiments have been carried out with
mice, and have established that the injection of adenovi-
rus recombinants into the mouse tail-vein leads to the
expression of their genes in approximately one-half of the
liver cells [12,13].
In the present study, we investigated gene targeting in the
mouse liver using a replication-defective adenovirus vec-
tor and a transgenic mouse system (Figure 1). Although
our initial attempts did not detect the predicted gene tar-
geting (the frequency of the expected recombinants was
less than 1/20,000 per lambda genome), the strategy and
methods detailed here will aid the development of virus-
mediated gene targeting in vivo.
Materials and methods
Bacteria, bacteriophages and plasmids
The bacteria, bacteriophages and plasmids used in this
study are listed together with details of their construction
in Additional file 1.
Experimental steps to detect gene targeting in vivo Figure 1
Experimental steps to detect gene targeting in vivo. 
Gene targeting in vivo in liver cells was attempted after the 
delivery of donor DNA with an adenovirus vector. The gene 
with the required sequence change (lacZ-) on the lambda 
transgene in the mouse will be detected after its recovery in 
bacteriophage particles. Only lacZ-negative mutants can form 
plaques under the selective conditions.
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BIK12001 was used for the titration of bacteriophage
lambda and the measurement of lacZ-negative bacteri-
ophage lambda by phenyl beta-D-galactoside (p-gal)
selection (see below). BIK1564 was used for the growth of
all bacteriophage lambda strains in this study. BIK2206
was used for confirmation of the LacZ-negative phenotype
of the bacteriophage selected with p-gal using 5-bromo-4-
chloro-3-indlyl-beta-D-galactose (X-gal).
The construction of the plasmids used in this study is
detailed in additional file 1. The construction of pAdNY58
is also illustrated in Figure 2. The construction of
pAdNY57 was as follows. The SmaI(1)-SacI fragment of
LIA7 within the lacZ gene (Figure 2) was used to replace
the shorter SmaI-SacI fragment of pUC18. The Glu461Gly
mutation (Figure 3) was introduced into the resulting
plasmid (pNY15) by site-directed mutagenesis using PCR
[14] as follows. The PCR products generated with the
primer pair LZG-U (5'-ACCGGCGATGAGCGAA-3') and
LZG-MA (5'-GCCTGATCCATTCCCCAGCGACCA-3'),
and the primer pair LZG-MS (5'-GGGAATGGATCAG-
GCCACGGCCGC-3') and LZG-D (5'-GGGCTGGTCT-
TCATCC-3'), were mixed and used as templates for the
second round of PCR with the primer pair LZG-U and
LZG-D. The MluI-BssHII fragment of the wild-type lacZ
gene of pNY15 was replaced by the MluI-BssHII fragment
of the PCR product. The targeted change in the resulting
plasmid (pNY15G3.11) was confirmed by sequencing.
pNY20 was produced by replacing the smaller SmaI-SacI
fragment of pNY19 with the homologous SmaI-SacI frag-
ment of pNY15G3.11, which carries the mutant sequence.
These two lacZ mutations were transferred back to lambda
by homologous recombination in vivo [15] in order to
generate LIA15 and LIA11, respectively. The recombina-
tional transfer was carried out as follows. Cells of
BIK12015 or BIK12018 were grown to OD600 = ~0.3 in LB
(10 g bactotrypton, 5 g yeast extract and 10 g NaCl per
liter) containing 20 µg/ml chloramphenicol, 0.2% mal-
tose and 10 mM MgSO4. LIA7 was adsorbed onto the cells
at a multiplicity of 1.0 at 37°C for 15 minutes. The mix-
ture was shaken at 37°C until the OD600 dropped below
0.3. One drop of CHCl3 was added to the mixture, which
was then shaken for 30 seconds. The mixture was centri-
fuged and the supernatant was recovered. The supernatant
was assayed for BIK12001 on agar plates containing p-gal
as detailed below. The plaques on the p-gal plates were
isolated and analyzed for the designed sequence change
by restriction of the PCR products (see Analysis of the
mutant bacteriophage DNA).
Selection of lacZ-negative bacteriophage with p-gal
The lacZ-negative bacteriophage particles were detected
using positive selection [15,16]. BIK12001 cells were
grown with shaking at 37°C to OD600 = 1.0 in LB contain-
ing ampicillin (50 µg/ml), kanamycin (20 µg/ml) and
0.2% maltose. The culture was centrifuged at 3,500 rpm
for 15 minutes at 4°C. The pellets were dissolved into
one-half the volume of LB containing 10 mM MgSO4. The
bacteriophage was adsorbed onto these cells at room tem-
perature for 20 minutes. To estimate the total number of
bacteriophages, 2.5 ml molten 1/4 LB top agar (5 g LB
broth base (Gibco BRL, Rockville, MD, USA), 6.4 g NaCl
and 7.5 g Bactoagar per liter) was added to 0.25 ml of the
mixture of cells and bacteriophages, and the entire con-
tent was poured onto a 1/4 LB plate (5 g LB broth base, 6.4
g NaCl and 15 g Bactoagar per liter). To estimate the
number of lacZ-negative bacteriophages, 2 ml of the mix-
ture of cells and bacteriophages, and 22 ml of molten 1/4
LB top agar containing 0.3% p-gal (Sigma Chemical Co.,
MO, USA), were mixed and poured onto four 1/4 LB
plates. The plates were incubated at 37°C for 12 hours.
Construction of recombinant adenoviruses
pNY56 was constructed by replacing the shorter XbaI-
BamHI fragment of pHM5 by the XbaI-BglII fragment of
pNY19 (Figure 2). pAdHM4 includes the entire genome of
the recombinant adenovirus vector. The plasmid
pAdNY56 was constructed by replacing the shorter I-CeuI-
PI-SceI fragment of pAdHM4 by an I-CeuI-PI-SceI frag-
ment of pNY56. The PacI fragment of pAdNY56 was trans-
fected into cells of cell-line 293, which allows replication
of the replication-defective adenoviruses. The recom-
binant adenovirus AdNY56 was prepared and purified as
described previously [18]. Similarly, AdNY57 was con-
structed from pNY20 via pNY57 (Additional file 1), and
AdNY58 was constructed from pNY21 via pNY58 (Figure
2, Additional file 1).
Adenovirus infection
Female MutaMice (7 weeks old) were obtained from Cov-
ance Research Products Inc. (Denver, PA, USA). The
MutaMice were maintained under specific pathogen-free
conditions in the animal faculty of the Institute of Medical
Science at the University of Tokyo, Japan. After the ani-
mals were anesthetized with Nembutal (Dainippon Phar-
maceutical Co., Osaka, Japan), 3 × 109 plaque-forming
units (PFU) of the recombinant adenovirus in 200 µl of
PBS (137 mM NaCl, 8.10 mM Na2HPO4, 2.68 mM KCl,
1.47 mM KH2PO4, 0.9 mM CaCl2, 0.33 mM MgCl2) was
injected into the tail-vein of each mouse using a 30-gauge
needle. AdNY56 was injected into one mouse, AdNY57
was injected into two mice and AdNY58 was injected into
two mice.
Isolation of genomic DNA, recovery of lambda 
bacteriophage and measurement of mutant frequency
Twenty-four hours after injection, the mice were sacri-
ficed. A lobe of the liver of each animal was excised, frozen
by submersion in liquid nitrogen and stored in a 1.5-mlGenetic Vaccines and Therapy 2005, 3:8 http://www.gvt-journal.com/content/3/1/8
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plastic tube at -80°C. Genomic DNA was isolated from
the liver tissue with phenol-chloroform and precipitated
by ethanol/sodium as described in the manual for Muta-
Mouse. Lambda bacteriophage particles were recovered
from the isolated DNA by incubation with packaging
extracts (Mutaplax, Epicentre, WI, USA). The lacZ-nega-
tive mutants were detected by p-gal selection as described
above. Each plaque on the selective agar was recovered in
100 µl of SM buffer (50 mM Tris-HCl (pH 7.5), 10 mM
MgSO4, 100 mM NaCl and 0.01% gelatin). In order to
verify the lacZ-negative phenotype, each isolate was
assayed on agar with X-gal using a spot assay as follows.
BIK2206 was grown in LB containing ampicillin (50 µg/
ml) and tetracycline (10 µg/ml). Twice-concentrated cul-
Construction of the recombinant adenovirus AdNY58 Figure 2
Construction of the recombinant adenovirus AdNY58. The bacteriophage lambda LIA7 was recovered from the Muta-
Mouse by in vitro packaging. An SmaI-SacI fragment of LIA7 within its lacZ gene was inserted into pIK153. The Tyr105Stop 
mutation (Figure 3) was introduced into the resulting plasmid (pIK153LZS.6) using site-directed mutagenesis by PCR as follows. 
The PCR products generated with the primer pair LZT-U (5'-CGAAGAGGCCCGCAC-3') and LZT-MA (5'-TAAT-
GGGCTAGGTTACGTTGGTGTAG-3'), and the primer pair LZT-MS (5'-TAACCTAGCCCATTACGGTCAATCC-3') and 
LZT-D (5'-GGCAACATGGAAATCGC-3') were mixed and used as templates for the second PCR with the primer pair LTZ-
U and LZT-D. Replacement of an FspI-AatII fragment of pIK153LZS.6 by the FspI-AatII fragment of the resulting PCR product 
resulted in pIK153 T10.1. A BamHI-SmaI fragment covering the lacZ gene of LIA7 was inserted into the BamHI site of pIK153 
(resulting in pNY19). pNY21 was made by replacing the smaller SmaI-SacI fragment of pNY19 with the homologous SmaI-SacI 
fragment of pIK153T10.1, which carries the mutant sequence. An XbaI-BglII fragment of pNY21 was used to replace the 
smaller XbaI-BamHI fragment of pHM5 (resulting in pNY58). pAdNY58 was made by replacement of the smaller I-CeuI-PI-SceI 
fragment of pAdHM4 with an I-CeuI-PI-SceI fragment of pNY58. The longer PacI fragment of pAdNY58 was transfected into 
293 cells. The recombinant adenovirus AdNY58 was prepared and purified from the cell culture.
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ture (1.25 ml) was mixed with 6 ml molten LB/MM agar
(100 ml LB medium, 0.75 g Bactoagar, 10 mM MgSO4,
0.2% maltose and 0.35 mg/ml X-gal) and spread on agar.
A 10-µl aliquot of each bacteriophage sample was spotted
onto these cells. The plates were incubated overnight at
37°C. The mutant frequency was estimated by dividing
the number of PFU on the selective plate (as verified with
X-gal) by the number of total PFU on 1/4 LB agar.
Analysis of the mutant bacteriophage DNA
The lacZ-negative lambda bacteriophage DNA from the
mice was analyzed using restriction enzymes following
PCR. For the lacZ-negative lambda DNA from the
AdNY57-treated mouse, PCR was carried out with the
primer pair LG-1 (5'-TACCGGCGATGAGCGAAC-3') and
LG-2 (5'-CTCCAGGTAGCGAAAGCC-3'). The 288-bp
product was purified by ethanol/sodium precipitation,
digested with TfiI (New England Biolabs, Beverly, MA,
USA) (recognition site, 5'-G|AWTC-3' (W = A or T)) at
65°C and analyzed using agarose electrophoresis. The
mutant sequence was resistant to TfiI, while the wild-type
sequence was sensitive, yielding 204 and 84 bp fragments.
The primer pair Lam-1 (5'-TACTGTCGTCGTCCCCTC-3')
and Lam-2 (5'-CGCAGATGAAACGCCGAGT-3') was used
for the lacZ-negative lambda DNA from the AdNY58-
treated mouse. The 213-bp PCR product was digested
with XspI (Takara Bio Inc., Shiga, Japan) (recognition site,
5'-C|TAG-3') at 37°C and analyzed using agarose electro-
phoresis. The wild-type sequence was resistant to XspI,
while the mutant sequence was sensitive, yielding 146
and 67 bp fragments.
Results
Experimental design for the detection of gene targeting in 
vivo
Figure 1 illustrates our experimental design for the sensi-
tive detection of gene targeting in vivo. The MutaMouse
carries approximately 40 copies of bacteriophage lambda
gt10lacZ on a chromosome [6,19]. The single integration
site is located in band C on chromosome 3 [20]. Our
target sequence was the wild-type lacZ gene. The donor
DNA was delivered to the liver cell nuclei by tail-vein
injection of the recombinant adenovirus. Genomic DNA
was isolated from the liver and its in vitro packaging
allowed the recovery of the lambda genome in viable bac-
teriophage particles. A lacZ-negative mutant bacteri-
ophage was selected as a plaque-former in an Escherichia
coli mutant defective in the galE gene on an agar plate
containing p-gal. This chemical is converted by the lacZ
gene product (beta-galactosidase) into UDP-galactose,
which accumulates in the absence of the GalE protein to
induce cell death. The ratio of the mutant plaque-formers
to the total plaque-formers was used to estimate the frac-
tion of the mutated gene. The mutant gene was further
analyzed using restriction enzymes.
Replication-defective recombinant adenoviruses con-
structed by an in vitro-ligation method were used to
deliver the donor DNA [18,21]. Figure 3 shows the
structure of the recombinant adenoviruses used in the
present study (see Figure 2, Additional file 1, and Materi-
als and methods for further details). An 8077-bp fragment
of lambda gt10lacZ was inserted into the E1 deletion site
of the mutant adenovirus [18,21]. AdNY56 had wild-type
lacZ, while AdNY57 and AdNY58 had a point mutation in
lacZ (Figure 3B).
AdNY57 was constructed so as to introduce a point muta-
tion at the active site of LacZ. The target sequence was the
5' GAA that codes for Glu461, which is essential for the
activity of LacZ [22,23]. AdNY57 was expected to change
its second base (that is, the 1437 th base) from A to G,
thereby generating the Glu461Gly mutant, which shows a
76-fold decrease in activity [23]. The mutant and wild-
type sequences can be distinguished using the restriction
enzyme TfiI (Figure 3B).
AdNY58 was constructed so as to introduce a point muta-
tion at the 5' TAT that codes for Tyr105. AdNY58 was
expected to change its third base (that is, the 369th base)
from T to G, thereby generating the Tyr105Stop mutant.
The mutant and wild-type sequences can be distinguished
using the restriction enzyme XspI (Figure 3B).
Control experiments
We demonstrated that lacZ mutants that were predicted to
be generated by the recombinant adenovirus could be
selected with p-gal as follows. Bacteriophage lambda
strains carrying the mutations were produced by transfer-
ring each mutation on a plasmid back to lambda through
homologous recombination in E. coli (as detailed in
Materials and methods). The two bacteriophage strains,
lambda gt10lacZ-  Tyr105Stop (LIA11) and lambda
gt10lacZ- Glu461Gly (LIA15), were then used in the p-gal
selection. As shown in Table 1, lambda with wild-type
lacZ showed a plaque-formation efficiency of less than 1/
10,000 on the selective agar relative to that on the non-
selective agar. By contrast, each of the mutant lambda
strains showed similar or slightly decreased plaque-for-
mation efficiency on the selective agar. We concluded that
the expected targeted product with AdNY57 and AdNY58,
if it was produced, should be selected and measured using
the p-gal-selection procedure.
Delivery of donor DNA and measurement of mutant 
frequency
The recombinant adenovirus particles (3 × 109 PFU in 200
µl of PBS) were injected into the tail-vein of a MutaMouse.
It is well established that the adenovirus genome accumu-
lates in the liver cell nuclei after tail-vein injection [12,13].
Most of the hepatocyte nuclei are expected to receive sev-Genetic Vaccines and Therapy 2005, 3:8 http://www.gvt-journal.com/content/3/1/8
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eral copies of the adenovirus genome under these condi-
tions (see Discussion). After 24 hours, the liver was
excised from the MutaMouse, genomic DNA was isolated
from the liver tissue and the lambda genome was recov-
ered as a bacteriophage particle by in vitro packaging. The
lacZ-negative phage was detected selectively on agar with
p-gal. The plaques on these selective plates were isolated
and the LacZ-negative phenotype was confirmed on agar
plates containing X-gal. The mutant frequency was esti-
mated as the fraction of the lacZ-negative phage (Table 2).
Design for gene targeting and its detection Figure 3
Design for gene targeting and its detection. (A) The donor carrying the mutant lacZ gene is inserted into an adenovirus 
vector. The lacZ mutation will be transferred to the lacZ gene of the lambda transgene in the mouse genome. (B) Expected 
sequence changes and their detection using restriction analysis.
Table 1: Selection efficiency of lambda lacZ-negative mutants
Lambda Genotype Titer Titer on p-gal selective 
plate
Relative plaque 
formation
LIA7 lacZ+ 2.2 × 1010 1.9 × 106 8.6 × 10-5
LIA11 lacZ- (Tyr105Stop) 9.6 × 1010 8.8 × 1010 9.2 × 10-1
LIA15 lacZ- (Glu461Gly) 1.4 × 1010 1.3 × 1010 9.1 × 10-1
Lambda transgene
(λgt10 lacZ )
in mouse genome 
Recombinant adenovirus
(AdNY57)
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lacZ-
 8.1 kb
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recombination
A.
B.
Wild type AdNY58 AdNY57
Glu461Gly
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288 bp
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+
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The control mouse (animal number 0) received no
injections.
The mutant frequencies of the AdNY56-injected and con-
trol mice were similar (Table 2, Experiment 1), and did
not differ significantly from those reported previously
using this method (see [15] and the references cited
therein). No significant increase in the mutant form of the
gene was induced by injection of the recombinant adeno-
virus: the mutant frequency of the AdNY57- and AdNY58-
injected mice was similar to that of the control mouse,
which was approximately 1/10,000 (Table 2).
All of the lacZ-negative bacteriophages were purified and
their lacZ genes were analyzed using restriction-enzyme
treatment of the PCR products (Figure 4). As shown in Fig-
ures 3B and 4A, the PCR product of the Glu461Gly
mutant, as predicted from the AdNY57 injection, could
not be cut with TfiI. By contrast, the wild-type and most of
the other possible mutants could be cut with TfiI. In fact,
all of the lacZ-negative bacteriophages from the AdNY57-
injected mouse were cleavable with this restriction
enzyme. As shown in Figure 3B and 4B, the PCR product
of the Tyr105Stop mutant, as predicted from the AdNY58
injection, could be cut with XspI. By contrast, the wild-
type and most of the other mutants could not be cut with
XspI. None of the lacZ-negative bacteriophages from the
AdNY58-injected mice were cleavable with this restriction
enzyme.
We did not detect the expected gene replacement in any of
the isolates. Moreover, the gene-correction frequency by
these adenovirus constructs was shown to be less than 1/
20,000 in the present system.
Discussion
Here we attempted to perform gene targeting in a trans-
genic mouse system that allowed the sensitive detection of
mutagenesis by various agents, such as those directly
interacting with DNA in the liver and other organs
[24,25]. The limit of sensitivity in this system was 1/
20,000 (see also [15]). This procedure might provide an
alternative to the PCR-based assay for gene targeting in
vivo, although our initial trials did not detect any of the
expected recombinants.
In the present system, the sensitivity appeared to be lim-
ited by the high level of spontaneous mutagenesis in the
target gene. The MutaMouse system was produced to
detect mutagenesis at numerous sites within a gene, rather
than to study gene targeting. Experimental designs involv-
ing the specific selection of homologous recombination
events, such as those used in the previous work in vitro [7],
would therefore be preferred.
Also, in the present system, a successful gene-targeting
event would not be distinguishable in the phenotype of
the mouse cell. In transgenic mice with a single copy of
the mutant lacZ  gene [26], correction to the wild-type
Restriction analysis of the lacZ-negative gene from mice  treated with a recombinant adenovirus Figure 4
Restriction analysis of the lacZ-negative gene from 
mice treated with a recombinant adenovirus. (A) 
AdNY57-injected mouse. The PCR product of the lambda 
bacteriophage DNA with primers that flank the target site is 
288 bp long. The wild-type PCR product is cut with TfiI into 
84 and 204 bp fragments, whereas the Glu461Ala mutant 
PCR product is not cut. Lane M: Marker DNA prepared by 
HinfI digestion of the plasmid pUC19; 1–12, lacZ-negative 
bacteriophages from animal number 2; lacZ+: Lambda bacteri-
ophage recovered from control mouse; lacZ-Glu461Gly: 
lambda bacteriophage LIA15. (B) AdNY58-injected mouse. 
The PCR product of the lambda bacteriophage DNA with 
primers that flank the target site is 213 bp long. The 
Tyr105Stop mutant PCR product is cut with XspI into 146 
and 67 bp fragments, whereas the wild-type product is not. 
Lane M: Marker DNA prepared by HinfI digestion of plasmid 
pUC19; 1–4, lacZ-negative bacteriophages from animal 
number 3; lacZ+: Lambda bacteriophage recovered from con-
trol mouse; lacZ-Tyr105Stop: lambda bacteriophage LIA11.
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Table 2: Detection of lacZ- phage
Packaging 
exp.
RAd Genotype Animal 
number
Packaging Total number 
of plaque 
formers
lacZ- 
plaques
Mutant Frequency Expected 
genotype
1 None Not relevant #0 Tube 1 4.5 × 104 48 . 9  ×  1 0 -5 n.t.
Tube 2 3.2 × 104 39 . 4  ×  1 0 -5 n.t.
Tube 3 8.5 × 104 89 . 4  ×  1 0 -5 n.t.
average 9.2 × 10-5
AdNY56 lacZ+ #1 Tube 4 8.5 × 104 89 . 4  ×  1 0 -5 n.t.
Tube 5 6.4 × 104 34 . 7  ×  1 0 -5 n.t.
Tube 6 8.8 × 104 11 . 1  ×  1 0 -5 n.t.
average 5.1 × 10-5
2 None Not relevant #0 Tube 7 4.9 × 104 5 10 × 10-5 n.t.
Tube 8 6.6 × 104 46 . 1  ×  1 0 -5 n.t.
Tube 9 5.1 × 104 10 20 × 10-5 n.t.
average 12 × 10-5
AdNY57 lacZ- (Glu461Gly) #2 Tube 10 3.8 × 104 6 16 × 10-5 0/6
Tube 11 3.0 × 104 7 23 × 10-5 0/7
Tube 12 4.5 × 104 9 20 × 10-5 0/9
average 20 × 10-5 total 0/22
3 None Not relevant #0 Tube 13 3.7 × 104 6 16 × 10-5 n.t.
Tube 14 6.0 × 104 58 . 3  ×  1 0 -5 n.t.
Tube 15 4.4 × 104 49 . 1  ×  1 0 -5 n.t.
average 11 × 10-5
AdNY57 lacZ- (Glu461Gly) #2 Tube 16 1.3 × 104 9 69 × 10-5 0/9
Tube 17 3.9 × 104 19 49 × 10-5 0/19
Tube 18 6.5 × 104 26 40 × 10-5 0/26
average 53 × 10-5 total 0/54
4 None Not relevant #0 Tube 19 2.6 × 105 88 . 5  ×  1 0 -5 n.t.
AdNY57 lacZ- (Glu461Gly) #3 Tube 20 1.6 × 105 56 . 3  ×  1 0 -5 0/5
Tube 21 4.1 × 105 98 . 6  ×  1 0 -5 0/9
average 1.5 × 10-5 total 0/14
5 None Not relevant #0 Tube 22 3.3 × 104 39 . 1  ×  1 0 -5 n.t.
AdNY58 lacZ- (Tyr105 Stop) #4 Tube 23 8.6 × 104 44 . 7  ×  1 0 -5 0/4
Tube 24 3.1 × 104 39 . 7  ×  1 0 -5 0/3
average 7.2 × 10-5 total 0/7
RAd: Recombinant adenovirus
n.t.: Not tested.Genetic Vaccines and Therapy 2005, 3:8 http://www.gvt-journal.com/content/3/1/8
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gene would result in a direct positive readout in the
mouse body (for example, through staining with dye).
However, as the authors admit, it would be difficult to
detect the targeting events with a high sensitivity. The
presence of multiple copies of the target gene would
improve the sensitivity because the lacZ+  allele is
dominant over, and epistatic to, the lacZ- alleles with
respect to the above phenotype. The MutaMouse carries
multiple (approximately 40) copies of the target gene,
which amount to 0.4% of the genome. This should be
able to improve the sensitivity of detection of gene target-
ing, although the sensitivity is limited by spontaneous
mutagenesis. In addition, the presence of tandem repeats
might have other types of negative effect on gene target-
ing, as detailed below.
How efficient is adenovirus infection and delivery to the
hepatocyte nucleus? Tail-vein injection is an established
method for the delivery of adenovirus to liver cells. The
average copy number of a replication-defective recom-
binant adenovirus genome per liver cell has been esti-
mated as 14–28 copies using Southern hybridization after
tail-vein injection of 5 × 109 PFU of the virus [12]. This
corresponds to 40% of the injected adenovirus. Fluores-
cence in situ hybridization revealed that, after tail-vein
injection of 2 × 109 PFU, all of the hepatocyte nuclei had
1–100 copies of a recombinant adenovirus genome, with
an average of 20 copies [27]. After tail-vein injection of 2
× 108 PFU of a recombinant adenovirus with the lacZ
expression cassette, 40% of the hepatocytes expressed
beta-galactosidase [13]. We assumed that the majority of
the liver cells received several copies of the adenovirus
genome, at least sufficient for gene expression, after inject-
ing 3 × 109 PFU in our experiment. (We cannot raise the
titer any more because of the toxicity of the virus.) This
type of information can be confirmed by Southern
hybridization and fluorescence in situ hybridization.
The gene-targeting frequency with recombinant adenovi-
ruses in vitro varies from ~10-7–10-4 per cell [7,8,28]. We
did not detect any signal using recombinant adenovirus
for gene delivery in the mouse liver. In order to achieve
gene targeting in vivo using an adenovirus vector or any
other means, it will be necessary to increase the frequency
of gene targeting. So how can we achieve this goal?
The efficiency of gene targeting in vitro varies from one
locus to another [29,30]. Such locus-dependence might
reflect drastic effects of the chromatin structure on the
frequency of homologous recombination [30,31]. Thus,
the target transgene could be placed at a different locus
that is known to be a hot spot in gene targeting in embry-
onic stem (ES) cells.
Repetitive sequences are methylated in the mouse genome
[32]. Ikehata and colleagues suggested that the whole cod-
ing region of the MutaMouse lacZ transgene is methylated
to a high degree at every CpG site [33]. One possible rea-
son for this phenomenon is that the CpG content of the
lacZ gene (9%) [34] is much higher than the average CpG
content of the mouse genome (~1%) [35]. Methyl-CpG
binding protein 2 (MeCP2) might bind to methylated
CpG and somehow compact chromatin [36]. Further-
more, Manuelidis analyzed the structure of a mouse chro-
mosome bearing a huge (~11 Mb) insert of a tandem-
repeated transgene (~1,000 copies) [37]. This transgene
was localized on an arm of chromosome 3 at a distance
from the centromere. According to Manuelidis, the
transgene is heterochromatic and highly condensed.
Therefore, the MutaMouse transgene might be hetero-
chromatic. The accessibility of nucleases to the hetero-
chromatic structure is lower than that of euchromatin
[38,39]. Reducing the copy number of the transgene and/
or using another transgene that is lower in CpG content
might increase gene targeting, although the decrease in
copy number might affect the sensitivity of detection. An
important experiment that can be done is to test whether
the coding region of the MutaMouse lacZ transgene is
really heterochromatic, using, for example, CHIP assay
with the antibody against the methylated histones and
PCR primers on the lacZ genes.
Chromosome replication is known to stimulate homolo-
gous recombination. Partial hepatectomies in mice might
stimulate liver cell proliferation and DNA replication,
which in turn might stimulate recombination. Hara et al.
(1999) reported that partial hepatectomies increased
mutagenesis with N-ethyl-N-nitrosourea, which is a
direct-acting DNA-ethylation agent, in the MutaMouse
[40].
It might be easier to modify the donor DNA than the
recipient DNA. One can generate recombinogenic damage
on the donor DNA. Irradiating adenovirus particles with
ultraviolet light of 1500 J/m2 resulted in an approximately
three-fold increase in their mutual homologous recombi-
nation [41]. Recombinogenic cross-links are induced by
some mutagens, such as psoralens, cisplatin (cis-diam-
minedichloroplatinum) and mitomycin C [42]. Such
agents, both mutagenic and recombinogenic, might be
suitable for gene targeting in vivo if they are shown to be
active in mutagenesis in a transgenic-reporter mouse sys-
tem. The effect of such recombinogenic damage might be
much larger with replication-defective adenovirus recom-
binants than with replication-competent adenoviruses,
because their replication-intermediates are responsible for
their high recombination frequency [41,43-45].Genetic Vaccines and Therapy 2005, 3:8 http://www.gvt-journal.com/content/3/1/8
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The gene-targeting frequency is strongly dependent on the
length of homology; the frequency increases as the
homology length increases up to 10 kb [46-48]. If the
deviation from this rule above 10 kb is due to the shearing
and/or degradation of longer DNA after electroporation
in embryonic stem cells, donor DNAs that are protected
by the DNA binding proteins in the adenovirus particle
might show greater length dependence over a wider range
of values. Adenoviral vectors with a larger capacity for
inserts, which are known as high-capacity 'gutless' vectors
[49-51] might therefore be suitable for use in this
approach.
Conclusion
Here we attempted to perform gene targeting in a trans-
genic mouse system that allowed the sensitive detection of
mutagenesis. The frequency of gene targeting in the
mouse liver by these recombinant adenoviruses was
shown to be less than 1/20000 with the sensitive and
PCR-independent detection system.
List of abbreviations
PCR, polymerase chain reaction; PFU, plaque-forming
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